Does Taking Valacyclovir Prevent Transmission?

Valacyclovir substantially reduces the risk of transmitting genital herpes to a partner, but it does not eliminate that risk entirely. The best evidence comes from a large randomized trial of monogamous couples in which one partner had genital HSV-2 and the other did not: daily valacyclovir cut overall transmission roughly in half and reduced symptomatic infections by about 75%. That still leaves a residual chance of passing the virus along, which is why clinicians typically recommend combining the medication with other precautions rather than relying on it alone.

What the Largest Transmission Trial Actually Found

The study most often cited on this question enrolled nearly 1,500 heterosexual, monogamous couples in which one partner had clinically symptomatic genital HSV-2 and the other was susceptible. The infected partners were randomly assigned to take either 500 mg of valacyclovir once daily or a placebo for eight months, while the susceptible partners were checked monthly for signs of infection.¹

Among susceptible partners who received placebo, about 3.6% acquired HSV-2 over those eight months. In the valacyclovir group, the figure dropped to about 1.9%, a roughly 48% reduction in overall acquisition. When the researchers looked only at infections that caused symptoms, the difference was even more dramatic: just 4 susceptible partners in the valacyclovir group developed symptomatic herpes compared with 16 in the placebo group, a 75% reduction.¹

These numbers deserve some context. A 48% reduction sounds impressive in relative terms, but in absolute terms the baseline risk in this trial was already fairly low: fewer than 4 out of 100 susceptible partners caught the virus over eight months even without medication. Valacyclovir brought that down to roughly 2 out of 100. For an individual couple, the per-encounter risk is tiny. But across a population of millions of discordant couples, even small absolute differences add up.

How Valacyclovir Lowers the Risk

Herpes is transmitted primarily through viral shedding at the skin’s surface, and most of that shedding happens without any visible symptoms. You can shed the virus on days when you feel perfectly fine and have no sores, which is why genital herpes spreads so efficiently. Valacyclovir works by reducing both the frequency and the amount of this invisible shedding.

In people newly diagnosed with genital herpes, daily valacyclovir cut subclinical shedding by about 78% compared with placebo. Participants shed on roughly 2.4% of days while taking the drug versus 11% of days on placebo.² A separate trial looked at people who were HSV-2 seropositive but had never been told they had genital herpes, a common scenario since most HSV-2 carriers don’t know they’re infected. In that group, valacyclovir still reduced subclinical shedding by about 71%, and 84% of participants on valacyclovir had no detectable shedding at all, compared with 54% on placebo.³

Valacyclovir itself isn’t the active drug. It’s a prodrug, meaning your body converts it into acyclovir after you swallow it. The advantage of taking valacyclovir over plain oral acyclovir is that you absorb much more of the active ingredient. The bioavailability of acyclovir delivered through valacyclovir is roughly three to five times higher than what you’d get from oral acyclovir tablets.⁴ In real-world conditions, when patients with recurrent genital herpes self-started treatment during outbreaks, valacyclovir delivered about 68% more acyclovir into the bloodstream than taking acyclovir directly.⁵ That higher absorption is what lets valacyclovir work with simpler dosing: once a day for suppression, rather than the multiple daily doses required with acyclovir.

Why Valacyclovir Doesn’t Eliminate Transmission Entirely

If the drug reduces shedding by 70–80%, you might wonder why it only reduces actual transmission by around half. The gap comes from the nature of herpes reactivation. HSV lives in nerve cells and periodically travels back to the skin surface in brief bursts. Even on suppressive therapy, these breakthrough reactivations still happen. A crossover study that tested standard-dose valacyclovir, high-dose acyclovir, and high-dose valacyclovir found that breakthrough shedding occurred at every drug dose tested. Most of these episodes were short and subclinical, but a meaningful fraction, around 20% on standard-dose therapy, carried high viral loads.⁶

Even high-dose valacyclovir didn’t eliminate these high-viral-load episodes. That finding has practical implications: simply taking more medication won’t close the remaining gap. The virus reactivates so quickly from its latent state that even sustained antiviral levels in the blood can’t always intercept every burst before infectious particles reach the skin surface. This is the fundamental limitation of all current antiviral suppressive therapy for herpes.

Suppressive Therapy Versus Taking It Only During Outbreaks

Valacyclovir can be taken two ways. Episodic therapy means you start a short course when you feel an outbreak coming on and stop when it resolves. Suppressive therapy means you take the drug every day regardless of symptoms. For reducing transmission, only daily suppressive therapy has solid evidence behind it. The landmark couples trial used daily dosing, and shedding studies measure shedding reduction under continuous use. When you take valacyclovir only during outbreaks, it shortens and softens the episode but does nothing about the invisible shedding that happens between outbreaks, which is when most transmission occurs.

That said, suppressive therapy also helps in ways beyond transmission. It reduces the number and severity of outbreaks, which means fewer days with symptoms and a lower chance of being caught off guard by a visible sore. For people who have frequent recurrences, the quality-of-life improvement from suppression alone is often reason enough to take it daily. The transmission benefit is an added layer on top of that personal benefit.⁷

Valacyclovir is the only oral antiviral approved for once-daily suppressive dosing, which makes adherence simpler compared with drugs that need to be taken two or three times a day.⁸ Adherence matters because the drug’s protective effect depends on keeping consistent antiviral levels in your body. Miss doses frequently and shedding rebounds.

Combining Valacyclovir with Other Precautions

Because valacyclovir cuts transmission by about half but can’t prevent it entirely, most guidelines recommend layering it with other strategies. Consistent condom use reduces herpes transmission on its own, and combining condoms with daily valacyclovir offers more protection than either approach alone. Avoiding sex during active outbreaks, when viral shedding tends to be heaviest, provides another layer. And disclosing your status to a partner so that both of you can make informed decisions is the foundation that makes all of these strategies work together.

None of these methods is individually foolproof. Condoms don’t cover all skin that can shed virus, and outbreaks aren’t the only time you’re contagious. But the combination of daily valacyclovir, consistent condom use, and outbreak avoidance brings the residual transmission risk down to a level that many discordant couples find manageable. For perspective, even in the placebo arm of the couples trial, fewer than 4 in 100 susceptible partners acquired the virus over eight months of unprotected sex. With all three strategies in place, the real-world risk per year of a committed relationship is quite low.

Pregnancy and Preventing Neonatal Herpes

Herpes transmission during childbirth is a different scenario from sexual transmission, but valacyclovir plays a role here too. Neonatal herpes, though rare, can be devastating, and the main risk factor is an active genital outbreak at the time of delivery. When that happens, the standard response is cesarean delivery to protect the newborn from direct contact with the virus.

A randomized trial of pregnant women with recurrent genital herpes found that starting valacyclovir at 36 weeks of gestation significantly reduced outbreaks at delivery. Only 4% of women in the valacyclovir group had a recurrence requiring cesarean delivery compared with 13% in the placebo group. HSV was detected by culture in 2% of the valacyclovir group versus 9% of those on placebo. No infants in either group were diagnosed with neonatal herpes.⁹ A broader review confirmed that prophylactic valacyclovir in late pregnancy reduces clinical recurrence, viral shedding at delivery, and the rate of cesarean sections performed for herpes.¹⁰

The biggest risk for neonatal herpes is actually a first-time maternal infection acquired late in pregnancy, because the mother hasn’t yet developed protective antibodies to pass to the baby. In that situation, valacyclovir can help manage the acute infection, but the risk to the newborn is substantially higher than in women with longstanding recurrent herpes. If your partner has herpes and you’re pregnant and seronegative, preventing your own acquisition during pregnancy becomes the priority.

People Living with HIV

The relationship between herpes and HIV is tangled in both directions. HSV-2 increases susceptibility to HIV, and HIV infection alters how herpes behaves. In people living with both viruses, herpes tends to reactivate more frequently and shed more heavily. Researchers hoped that suppressive antiviral therapy might reduce HIV transmission by calming herpes-related inflammation in the genital tract.

The results have been mixed. A trial comparing valacyclovir and acyclovir in people co-infected with HIV and HSV-2 found essentially identical genital HSV-2 shedding rates between the two drugs.¹¹ And a separate trial among Zimbabwean sex workers found that while acyclovir sharply reduced HSV-2 genital shedding, it had no effect on genital HIV shedding, even in participants with high adherence.¹² The hope that herpes suppression could meaningfully reduce HIV transmission at a population level has largely not been borne out, though suppressive therapy still helps HIV-positive individuals manage their herpes symptoms and outbreaks.

Safety During Long-Term Suppression

Since suppressive therapy means taking a pill every day, possibly for years, side effects matter. For most people, daily valacyclovir at 500 mg is well tolerated. The most commonly reported side effects are headache and nausea, and these tend to be mild. The more serious concern is kidney-related. Both acyclovir and valacyclovir require dose adjustments in people with impaired kidney function, because the drug is cleared through the kidneys and can crystallize in the renal tubules if levels build up too high.¹³

Kidney injury from valacyclovir has been documented in case reports, particularly in people who were dehydrated, elderly, or had pre-existing renal problems.¹⁴ At the suppressive dose of 500 mg daily in a person with normal kidneys, this is rare. Staying well hydrated and having periodic kidney function checks, especially early on, is standard good practice. If you have kidney disease or take other drugs that affect the kidneys, your doctor will typically adjust the dose or monitor more closely.

Antiviral Resistance

With any long-term antiviral therapy, resistance is a reasonable concern. Because valacyclovir is converted to acyclovir in the body, resistance to one means resistance to the other. Resistance arises mainly from mutations in two viral genes: one encoding an enzyme called thymidine kinase that the virus uses to activate acyclovir inside infected cells, and another encoding the viral DNA-copying machinery. Mutations in the thymidine kinase gene are the more common route to resistance.¹⁵

In people with healthy immune systems, clinically significant acyclovir resistance is uncommon, even with years of suppressive use. The immune system contributes to controlling the virus alongside the drug, so partially resistant strains tend to get suppressed anyway. Resistance becomes a more practical problem in immunocompromised patients, such as organ transplant recipients or people with advanced HIV, where the immune system can’t clean up viruses that escape the drug. If resistance does develop, alternative antivirals like foscarnet or cidofovir are available, though they’re less convenient and have more side effects.

The Cost and Adherence Question

Valacyclovir has been available in generic form for years, and the price has dropped considerably. For many people with insurance, a 30-day supply at the suppressive dose is inexpensive. But cost is only one piece of the puzzle. A public health analysis noted that while suppressive therapy reduces both the physical and psychological burdens of genital herpes and saves certain healthcare costs, the number of people who need to be treated to prevent one transmission is high, given the already-low per-couple risk. This makes a population-wide suppressive therapy program economically challenging, even though it can be highly worthwhile for individual discordant couples who want to minimize their specific risk.⁷

Adherence is the practical bottleneck. Shedding reduction depends on maintaining consistent drug levels, and missed doses create windows in which the virus can reactivate freely. Studies measuring pill-count adherence suggest that many participants in clinical trials take their medication reliably, but real-world adherence outside of a trial setting tends to be lower. If you’re taking valacyclovir specifically to protect a partner, consistency matters more than it would if you were just managing your own symptoms, because a shedding episode you never notice can still lead to transmission.

What About HSV-1 Genital Herpes

Most of the transmission data discussed above involves HSV-2, which historically has been the dominant cause of genital herpes. But HSV-1, traditionally associated with oral cold sores, is an increasingly common cause of genital infection, especially through oral sex. Genital HSV-1 behaves differently from genital HSV-2 in several ways: it recurs less often, sheds less frequently, and is less efficiently transmitted genitally. The landmark couples trial specifically studied HSV-2 discordant couples, so its 48% transmission-reduction figure may not translate directly to genital HSV-1 situations.

Valacyclovir is active against both HSV-1 and HSV-2, and it reduces shedding for both types. Clinicians do prescribe it for genital HSV-1 suppression in people who have frequent recurrences. However, because genital HSV-1 already recurs and sheds much less often than genital HSV-2, the marginal benefit of daily suppression for transmission prevention is less clear. Some people with genital HSV-1 who rarely or never have outbreaks may reasonably decide that daily medication isn’t necessary for their situation, especially if they’re already using condoms.

When People Don’t Know They Have Herpes

A complication that no pill can fully address is unrecognized infection. The majority of people with HSV-2 have never been diagnosed, either because they’ve never had noticeable symptoms or because their symptoms were mild enough to be mistaken for something else. One shedding study specifically recruited HSV-2 seropositive individuals who had no history of genital herpes and demonstrated that they still shed virus subclinically, and that valacyclovir significantly reduced their shedding.³ The problem, of course, is that people who don’t know they’re infected aren’t going to take suppressive therapy in the first place. This is a major reason why herpes continues to spread despite the availability of effective antiviral medication.

Type-specific blood tests can identify HSV-2 antibodies in people who’ve never had recognized symptoms, but routine screening is controversial. False positives are a concern at low antibody levels, and the psychological impact of a positive result in someone who has never had symptoms is debated. Still, for people in discordant relationships, or those who want to know their status before relying on assumptions, serologic testing is the main tool available. Knowing your status is what makes informed decisions about suppressive therapy, condoms, and disclosure possible in the first place.